Cassava Sciences Inc Total Liabilities
Cassava Sciences Inc total liabilities. Based on the latest financial reports, Cassava Sciences Inc (SAVA) has total liabilities worth $40.23 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cassava Sciences Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cassava Sciences Inc (1999–2025)
Total liabilities of Cassava Sciences Inc from 1999 to 2025. This chart illustrates how Cassava Sciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Cassava Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Cassava Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crown Confectionery Co Ltd
KO:264900
|
Korea | ₩127.95 Billion |
|
NFON AG
XETRA:NFN
|
Germany | €31.93 Million |
|
Maan Aluminium Limited
NSE:MAANALU
|
India | Rs1.18 Billion |
|
RenovoRx Inc
NASDAQ:RNXT
|
USA | $2.49 Million |
|
Taiwan Pelican Express Co Ltd
TW:2642
|
Taiwan | NT$1.76 Billion |
|
Citius Oncology, Inc.
NASDAQ:CTOR
|
USA | $71.71 Million |
|
MS Autotech Co.Ltd
KQ:123040
|
Korea | ₩1.06 Trillion |
|
FineMat Applied Materials Co Ltd
TW:6698
|
Taiwan | NT$963.77 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Cassava Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cassava Sciences Inc asset portfolio.
Liquidity & Leverage Metrics
Cassava Sciences Inc Total Liabilities Ratios Explained
Cassava Sciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cassava Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cassava Sciences Inc (1999–2025)
The table below shows the annual total liabilities of Cassava Sciences Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.95 Million | +271.56% |
| 2024-12-31 | $11.83 Million | -16.67% |
| 2023-12-31 | $14.20 Million | +94.59% |
| 2022-12-31 | $7.29 Million | -43.30% |
| 2021-12-31 | $12.87 Million | +512.71% |
| 2020-12-31 | $2.10 Million | +51.41% |
| 2019-12-31 | $1.39 Million | +171.43% |
| 2018-12-31 | $511.00K | -54.86% |
| 2017-12-31 | $1.13 Million | +70.23% |
| 2016-12-31 | $665.00K | -73.93% |
| 2015-12-31 | $2.55 Million | +200.12% |
| 2014-12-31 | $850.00K | -52.80% |
| 2013-12-31 | $1.80 Million | -95.88% |
| 2012-12-31 | $43.72 Million | -19.88% |
| 2011-12-31 | $54.57 Million | -17.65% |
| 2010-12-31 | $66.26 Million | -10.16% |
| 2009-12-31 | $73.75 Million | -17.27% |
| 2008-12-31 | $89.15 Million | -14.04% |
| 2007-12-31 | $103.71 Million | -20.55% |
| 2006-12-31 | $130.54 Million | -14.36% |
| 2005-12-31 | $152.44 Million | +1855.30% |
| 2004-12-31 | $7.80 Million | +97.32% |
| 2003-12-31 | $3.95 Million | +27.41% |
| 2002-12-31 | $3.10 Million | +23.08% |
| 2001-12-31 | $2.52 Million | +2.74% |
| 2000-12-31 | $2.45 Million | +715.86% |
| 1999-12-31 | $300.59K | -- |
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassav… Read more